A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV48108
Phase of Trial: Phase I
Latest Information Update: 04 Sep 2015
At a glance
- Drugs TV 48108 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 28 Aug 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 21 Aug 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 21 Aug 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.